Q32 Bio And Horizon Therapeutics Announce Dosing Of First Patient In Phase 2 Trial Of Bempikibart For Severe Alopecia Areata
Portfolio Pulse from Benzinga Newsdesk
Q32 Bio and Horizon Therapeutics have announced the dosing of the first patient in a Phase 2 trial of Bempikibart for severe Alopecia Areata. Alopecia Areata is the second autoimmune indication being evaluated for Bempikibart.
September 13, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Horizon Therapeutics is involved in a Phase 2 trial of Bempikibart for severe Alopecia Areata. This could potentially expand the company's product portfolio.
Horizon Therapeutics is directly involved in the Phase 2 trial of Bempikibart. If the trial is successful, it could lead to a new product for the company, potentially boosting its revenues and stock price in the future.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100